Clarus Therapeutics (OTCMKTS:CRXTQ) is a specialty biopharmaceutical company focused on the development and commercialization of proprietary drug delivery systems. Headquartered in Deerfield, Illinois, the firm is structured to leverage formulation technologies that enhance the safety, efficacy and convenience of well‐characterized therapeutic compounds. Clarus’ platform approach targets both pain management and pulmonary delivery applications.
The company’s lead product candidate, CT‐3, is a sublingual spray formulation of fentanyl designed for the rapid management of breakthrough cancer pain. CT‐3 has been developed under a U.S. Food and Drug Administration Special Protocol Assessment, and Clarus holds exclusive global rights for its commercial development. The sublingual delivery mechanism seeks to provide an alternative to traditional opioid administration routes, offering a rapid onset of action along with dose precision.
Beyond pain management, Clarus is evaluating additional pipeline candidates that exploit its delivery platform for respiratory diseases. These preclinical programs include inhalation formulations intended to improve therapeutic outcomes in pulmonary conditions. By focusing on proprietary formulations of known molecules, Clarus aims to mitigate the technical and regulatory risks typically associated with novel chemical entities.
Founded in 2010, Clarus Therapeutics conducts its research, development and regulatory activities primarily within the United States. The company’s management team brings together experience in specialty pharmaceuticals, clinical development and regulatory affairs. Clarus continues to engage with strategic partners and contract research organizations to advance its programs toward commercialization.
AI Generated. May Contain Errors.
